期刊文献+

不同基因作为竞争性内源RNA参与膀胱癌调控的研究进展 被引量:1

Research progress of different genes as ceRNA involved in bladder cancer regulation
下载PDF
导出
摘要 竞争性内源RNA(competing endogenous RNA,ceRNA)是一种新的转录后RNA相互调控机制,越来越多的研究发现长链非编码RNA(long non-coding RNA,lncRNA)、环状RNA(circular RNA,circRNA)和假基因(pseudogenes)可以与微小RNA(microRNA,miRNA)竞争,影响靶RNA的稳定性或翻译,从而调控基因表达。近年来,不同基因作为ceRNA参与膀胱癌调控的研究已引起学者的广泛关注。为此,本文综述了lncRNA、circRNA和假基因作为ceRNA在膀胱癌中作用的研究进展,以及不同基因作为ceRNA调控膀胱癌的信号转导通路。从ceRNA分类的角度综述各类ceRNA在膀胱癌发生发展过程中的研究进展。 Competing endogenous RNA is a new RNA transcription regulatory mechanism.More and more studies have found that lncRNA,circRNA and pseudogenes that can compete with miRNA,influence the stability of the target RNA or translation,thus regulate gene expression.In recent years,the involvement of different genes as ceRNA in the regulation of bladder cancer has attracted extensive attention of researchers.To this end,this paper reviewed the research progress of lncRNA,circRNA and pseudogenes as ceRNA in bladder cancer,as well as the signal transduction pathways in bladder cancer regulated by different genes as ceRNA.The research progress of ceRNA in bladder cancer is reviewed from the perspective of ceRNA classification.
作者 孔钰琳 荣胜忠 王慧单 李晓霞 KONG Yulin;RONG Shengzhong;WANG Huidan;LI Xiaoxia(Mudanjiang Medical University,Heilongjiang Mudanjiang 157011,China)
出处 《现代肿瘤医学》 CAS 北大核心 2021年第20期3662-3668,共7页 Journal of Modern Oncology
基金 国家自然科学基金资助项目(编号:81872703)。
关键词 膀胱癌 ceRNA lncRNA circRNA MIRNA bladder cancer ceRNA lncRNA circRNA miRNA
  • 相关文献

参考文献4

二级参考文献34

  • 1Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation[J]. Pharmacol Rev,2000, 52(2): 237 - 268.
  • 2Gille H, Kowalslki J, Li B, et al. Analysis of biological effects and signaling properties of Flt - 1 (VEGFR - 1 ) and KDR (VEGFR- 2)[J]. J Biol Chem, 2001, 276(5): 3222-3230.
  • 3Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3 - kinase/Akt signal transduction pathway[J]. J Biol Chem, 1998, 273(46): 30336-30343.
  • 4Zeng H, Sanyal S, Mukhopadhyay D. Tyrosine residues 951and 1 059 of vascular endothelial growth factor receptor- 2(KDR) are essential for vascular permeability factor/vascular endothelial growth factor- induced endothelium migration and proliferation, res
  • 5Neufeld G, Cohen T, Gengrinovitch S, et al. Vascular endothelial growth factor (VEGF) and its receptors[J]. FASEB J, 1999, 13(1): 9-22.
  • 6ShenBQ, Lee DY, GerberHP, etal. Homologous up- regu-lation of KDR/Flk - 1 receptor expression by vascular endothelial growth factorin vitro[J]. J Biol Chem, 1998, 273(45): 29979 - 29985.
  • 7Takahashi T, Shibuya M. The 230 kDa mature form of KDR/Flk- 1 (VEGF receptor- 2) activates the PLC- γ pathway and partially induces mitotic signals in NIH3T3 fibroblasts[ J].Oncogen, 1997, 14(17): 2079 - 2089.
  • 8Millauer B, Wizigmann- Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest Flk - 1 as a major regulator of vasculogenesis and angiogenesis[J]. Cell, 1993, 72(6): 835 - 846.
  • 9Arbiser JL, Larsson H, Claesson- Welsh L, et al. Overexpression of VEGF 121 in immortalized endothelial cells causes conversion to slowly growing angiosarcoma and high level expression of the VEGF receptors VEGFR- 1 and VEGFR- 2in vivo[J]. Am J Pathol, 20
  • 10Fuh G, Li B, Crowley C, et al. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor[J]. J Biol Chem, 1998, 273(18): 11197-11204.

共引文献61

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部